title: Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation.
abstract: Glioblastoma represent the most frequent primary tumors of the central nervous system and remain among the most aggressive human cancers as available therapeutic approaches still fail to contain their invasiveness. Many studies have reported elevated expression of the Focal Adhesion Kinase (FAK) protein in glioblastoma, associated with an increase in the rates of both migration and invasion. This designates FAK as a promising target to limit invasiveness in glioblastoma. Thymoquinone (TQ), the main phytoactive compound of Nigella sativa has shown remarkable anti-neoplasic activities on a variety of cancer cells. Here, we studied the anti-invasive and anti-migratory effects of TQ on human glioblastoma cells. The results obtained indicated that TQ treatment reduced migration, adhesion and invasion of both U-87 and CCF-STTG1 cells. This was accompanied by a drastic down-regulation of FAK, associated with a reduction of ERK phosphorylation as well as MMP-2 and MMP-9 secretion. This study provides new data on FAK regulation by a natural product (TQ) which could be of a great value for the development of novel therapies in glioblastoma.
authors.affiliation: Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, CNRS UMR 7213, 74 route du Rhin, B.P. 60024, 67401, Illkirch, France.
authors.forename: Kaouther
authors.initials: K
authors.lastname: Kolli-Bouhafs
authors.forename: Abdelaziz
authors.initials: A
authors.lastname: Boukhari
authors.forename: Abdurazzag
authors.initials: A
authors.lastname: Abusnina
authors.forename: Emilie
authors.initials: E
authors.lastname: Velot
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Gies
authors.forename: Claire
authors.initials: C
authors.lastname: Lugnier
authors.forename: Philippe
authors.initials: P
authors.lastname: Rondé
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D016227:Benzoquinones / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D015536:Down-Regulation; D005347:Fibroblasts / Q000187:drug effects / Q000502:physiology; D051417:Focal Adhesion Kinase 1 / Q000378:metabolism*; D005909:Glioblastoma; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D031881:Nigella sativa
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016227:Benzoquinones; D051417:Focal Adhesion Kinase 1; C496050:PTK2 protein, human; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; C003466:thymoquinone